SCHEMBL6493428

SCHEMBL6493428

CCN(c1cccc(Cl)c1)c1ncnc(Cl)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 5/20 0.39
MAPT P10636 2/20 0.37
EGFR P00533 4/20 0.36
CSF1R P07333 2/20 0.36
MEN1 O00255 1/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
NOS2 P35228 4/20 0.36
ALDH1A1 P00352 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MAP4K4 O95819 1/20 0.35
GRM5 P41594 1/20 0.35
NOS1 P29475 2/20 0.35
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
HTR3A P46098 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4947246 0.81 EGFR (0.47) TAAR1MAPTEGFRCSF1RHTT
SCHEMBL6487453 0.81 ALDH1A1 (0.34) MAPTEGFRTSHRKMT2AALDH1A1
SCHEMBL8441187 0.79 DHFR (0.43) TAAR1MAPTALDH1A1TDP1CRHBP
SCHEMBL2860699 0.71 TAAR1 (0.43) TAAR1MAPTEGFRCSF1RNOS2
SCHEMBL8334197 0.70 ALDH1A1 (0.66) MAPTEGFRCSF1RMEN1TSHR
SCHEMBL8344153 0.70 MT-CO2 (0.36) MAPTEGFRCSF1RALDH1A1NPSR1
SCHEMBL1323657 0.69 TDP1 (0.45) MAPTMEN1TSHRHTTKMT2A
SCHEMBL9004423 0.68 ALDH1A1 (0.63) MAPTTSHRHTTALDH1A1TDP1
SCHEMBL28015022 0.68 MAPT (0.42) TAAR1MAPTHTTNOS2ALDH1A1
SCHEMBL6184794 0.67 EGFR (0.76) MAPTEGFRCSF1RMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6881737-B2 Substituted triazinyl acrylamide derivatives and methods of use AMGEN INC. (US) 2005-04-19 US disclosed
EP-1390354-A1 TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS Amgen Inc. (US) 2004-02-25 EP disclosed
US-20030139416-A1 Substituted triazinyl acrylamide derivatives and methods of use AMGEN INC. 2003-07-24 US disclosed
WO-2002083653-A1 TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS AMGEN INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139416-A1 Substituted triazinyl acrylamide derivatives and methods of use PKD1, PKD2, GLS TAAR1 1477/4885MAPT 4216/4885EGFR 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.